Klaria Pharma Holding AB (publ.) (STO:KLAR)

Market Cap	122.99M
Revenue (ttm)	11.11M
Net Income (ttm)	-45.16M
Shares Out	245.98M
EPS (ttm)	-0.32
PE Ratio	n/a
Forward PE	5.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	271,648
Average Volume	599,199
Open	0.5360
Previous Close	0.5360
Day's Range	0.5000 - 0.5360
52-Week Range	0.2820 - 1.8100
Beta	0.96
RSI	45.96
Earnings Date	Aug 29, 2025

About STO:KLAR

Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction; and Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. The company is also involved in commercialization and sale of...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Employees: 4
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: KLAR

Financial Performance

In 2024, STO:KLAR's revenue was 2.25 million, a decrease of -73.41% compared to the previous year's 8.45 million. Losses were -47.75 million, 33.4% more than in 2023.